CA3222584A1 - Use of gabaa receptor modulators for treatment of itch - Google Patents
Use of gabaa receptor modulators for treatment of itch Download PDFInfo
- Publication number
- CA3222584A1 CA3222584A1 CA3222584A CA3222584A CA3222584A1 CA 3222584 A1 CA3222584 A1 CA 3222584A1 CA 3222584 A CA3222584 A CA 3222584A CA 3222584 A CA3222584 A CA 3222584A CA 3222584 A1 CA3222584 A1 CA 3222584A1
- Authority
- CA
- Canada
- Prior art keywords
- unsubstituted
- substituted
- phenyl
- alkyl
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16153035.7 | 2016-01-27 | ||
| EP16153035 | 2016-01-27 | ||
| EP16178824.5 | 2016-07-11 | ||
| EP16178824 | 2016-07-11 | ||
| CA3012791A CA3012791C (en) | 2016-01-27 | 2017-01-27 | Use of gabaa receptor modulators for treatment of itch |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3012791A Division CA3012791C (en) | 2016-01-27 | 2017-01-27 | Use of gabaa receptor modulators for treatment of itch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3222584A1 true CA3222584A1 (en) | 2017-08-03 |
Family
ID=57890845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3222584A Pending CA3222584A1 (en) | 2016-01-27 | 2017-01-27 | Use of gabaa receptor modulators for treatment of itch |
| CA3012791A Active CA3012791C (en) | 2016-01-27 | 2017-01-27 | Use of gabaa receptor modulators for treatment of itch |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3012791A Active CA3012791C (en) | 2016-01-27 | 2017-01-27 | Use of gabaa receptor modulators for treatment of itch |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10786513B2 (https=) |
| EP (1) | EP3407886A1 (https=) |
| JP (2) | JP7115746B2 (https=) |
| KR (1) | KR102482200B1 (https=) |
| CN (1) | CN108697694B (https=) |
| AU (1) | AU2017213154B2 (https=) |
| BR (1) | BR112018015386A2 (https=) |
| CA (2) | CA3222584A1 (https=) |
| CL (1) | CL2018002023A1 (https=) |
| IL (1) | IL260775B (https=) |
| MX (1) | MX388862B (https=) |
| SG (1) | SG11201806393QA (https=) |
| UA (1) | UA125463C2 (https=) |
| WO (1) | WO2017129801A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201806393QA (en) | 2016-01-27 | 2018-08-30 | Univ Zuerich | Use of gabaa receptor modulators for treatment of itch |
| JP7449272B2 (ja) * | 2018-04-18 | 2024-03-13 | ニューロサイクル・セラピューティクス・インコーポレイテッド | Ｇａｂａａ陽性アロステリックモジュレーター化合物、その作製の方法および使用 |
| WO2019226820A1 (en) | 2018-05-22 | 2019-11-28 | Neurocycle Therapeutics, Inc. | Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis |
| KR102712565B1 (ko) | 2018-09-13 | 2024-10-02 | 사니오나 에이/에스 | Gabaa 수용체 리간드 |
| SG11202109526PA (en) * | 2019-03-18 | 2021-10-28 | Neurocycle Therapeutics Inc | Use of gabaa receptor modulators for treatment of pain |
| CN110004118B (zh) * | 2019-03-29 | 2023-03-28 | 中国科学院武汉物理与数学研究所 | 用于辅助重组狂犬病毒在神经细胞高效逆向跨单级突触的rAAV病毒的包装方法及其应用 |
| KR20220087507A (ko) * | 2019-10-23 | 2022-06-24 | 뉴로사이클 테라퓨틱스, 인크. | Gabaa 수용체 조절제를 사용한 간질 병태의 치료 |
| US12233070B2 (en) * | 2020-06-30 | 2025-02-25 | University Of Mississippi Medical Center | Methods for treating benzodiazepine misuse/use disorder |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1024526A (en) | 1911-07-25 | 1912-04-30 | George R Schweikert | Chair. |
| ES2194205T3 (es) | 1996-07-25 | 2003-11-16 | Merck Sharp & Dohme | Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba. |
| FR2767692B1 (fr) * | 1997-09-01 | 2000-03-03 | Oreal | Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles |
| GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| GB9903119D0 (en) * | 1999-02-11 | 1999-04-07 | Merck Sharp & Dohme | Therapeutic agents |
| GB0117277D0 (en) | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| CA2427779A1 (en) | 2000-11-10 | 2002-05-16 | Merck Sharp & Dohme Limited | Imidazo-triazine derivatives as ligands for gaba receptors |
| TWI248936B (en) | 2001-03-21 | 2006-02-11 | Merck Sharp & Dohme | Imidazo-pyrimidine derivatives as ligands for GABA receptors |
| DE60319812T2 (de) | 2002-03-28 | 2009-04-23 | Wisys Technology Foundation, Inc., Madison | Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen |
| US8835424B2 (en) | 2002-03-28 | 2014-09-16 | Wisconsin Alumni Research Foundation | Selective agents for pain suppression |
| GB0210124D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| JP2004170323A (ja) * | 2002-11-22 | 2004-06-17 | Sumitomo Pharmaceut Co Ltd | 皮膚疾患治療剤のスクリーニング方法 |
| JPWO2005030773A1 (ja) * | 2003-09-26 | 2006-12-07 | 大日本住友製薬株式会社 | 新規ピラゾロピリミジン誘導体 |
| US20050245517A1 (en) * | 2004-04-29 | 2005-11-03 | Phil Skolnick | 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones |
| WO2006061428A2 (en) * | 2004-12-10 | 2006-06-15 | Universität Zürich | Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
| KR20060087386A (ko) * | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
| KR20090047450A (ko) | 2006-08-04 | 2009-05-12 | 메르츠 파마 게엠베하 운트 코. 카가아 | 치환된 피라졸로피리미딘, 이의 제조 방법 및 의약품으로서의 이의 용도 |
| ME02372B (me) | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
| WO2009021957A2 (en) * | 2007-08-14 | 2009-02-19 | Novartis Ag | Tricyclic heterocyclic compounds as gaba a modulators |
| WO2009143211A2 (en) | 2008-05-21 | 2009-11-26 | Incyte Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| US8455476B2 (en) | 2009-04-22 | 2013-06-04 | Janssen Pharmaceutica, Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| US20110082147A1 (en) | 2009-07-24 | 2011-04-07 | Concert Pharmaceuticals, Inc. | Substituted imidazotriazines |
| JP5894161B2 (ja) | 2010-08-25 | 2016-03-23 | ネオファーム カンパニー， リミテッド | 新規の複素環化合物及びこれを用いた炎症性疾患治療用組成物 |
| US20130331394A1 (en) | 2012-06-11 | 2013-12-12 | The Mclean Hospital Corporation | Treating schizophrenia |
| MX362181B (es) * | 2013-02-19 | 2019-01-08 | Ono Pharmaceutical Co | Compuesto inhibidor de cinasa del receptor de tropomiosina (trk). |
| WO2015072853A1 (en) * | 2013-11-13 | 2015-05-21 | Rjg Developments B.V. | Treatment of herpes virus infection outbreaks |
| GB201321732D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| CA2979701C (en) | 2015-03-20 | 2023-01-03 | Uwm Research Foundation, Inc. | Oxazole substituted benzimidazodiazepines and their uses as gabaergic ligands |
| SG11201806393QA (en) | 2016-01-27 | 2018-08-30 | Univ Zuerich | Use of gabaa receptor modulators for treatment of itch |
-
2017
- 2017-01-27 SG SG11201806393QA patent/SG11201806393QA/en unknown
- 2017-01-27 CN CN201780008490.1A patent/CN108697694B/zh not_active Expired - Fee Related
- 2017-01-27 UA UAA201808382A patent/UA125463C2/uk unknown
- 2017-01-27 JP JP2018539149A patent/JP7115746B2/ja active Active
- 2017-01-27 KR KR1020187022974A patent/KR102482200B1/ko active Active
- 2017-01-27 BR BR112018015386-9A patent/BR112018015386A2/pt not_active IP Right Cessation
- 2017-01-27 EP EP17701549.2A patent/EP3407886A1/en active Pending
- 2017-01-27 CA CA3222584A patent/CA3222584A1/en active Pending
- 2017-01-27 WO PCT/EP2017/051866 patent/WO2017129801A1/en not_active Ceased
- 2017-01-27 CA CA3012791A patent/CA3012791C/en active Active
- 2017-01-27 AU AU2017213154A patent/AU2017213154B2/en not_active Expired - Fee Related
- 2017-01-27 MX MX2018009252A patent/MX388862B/es unknown
-
2018
- 2018-07-25 US US16/045,193 patent/US10786513B2/en active Active
- 2018-07-25 IL IL260775A patent/IL260775B/en unknown
- 2018-07-26 CL CL2018002023A patent/CL2018002023A1/es unknown
-
2020
- 2020-08-14 US US16/994,146 patent/US11529359B2/en active Active
-
2022
- 2022-04-04 JP JP2022062494A patent/JP2022088620A/ja active Pending
- 2022-09-01 US US17/901,356 patent/US12433898B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| UA125463C2 (uk) | 2022-03-16 |
| RU2018128905A3 (https=) | 2020-03-24 |
| US20210100814A1 (en) | 2021-04-08 |
| WO2017129801A1 (en) | 2017-08-03 |
| MX388862B (es) | 2025-03-20 |
| CN108697694B (zh) | 2022-12-09 |
| JP2019507736A (ja) | 2019-03-22 |
| US20250268912A1 (en) | 2025-08-28 |
| IL260775B (en) | 2021-09-30 |
| SG11201806393QA (en) | 2018-08-30 |
| US11529359B2 (en) | 2022-12-20 |
| US10786513B2 (en) | 2020-09-29 |
| AU2017213154B2 (en) | 2023-02-02 |
| JP7115746B2 (ja) | 2022-08-09 |
| CA3012791C (en) | 2024-01-23 |
| KR20180118623A (ko) | 2018-10-31 |
| JP2022088620A (ja) | 2022-06-14 |
| BR112018015386A2 (pt) | 2019-03-19 |
| AU2017213154A1 (en) | 2018-08-16 |
| CN108697694A (zh) | 2018-10-23 |
| CA3012791A1 (en) | 2017-08-03 |
| MX2018009252A (es) | 2019-01-21 |
| RU2018128905A (ru) | 2020-02-27 |
| EP3407886A1 (en) | 2018-12-05 |
| CL2018002023A1 (es) | 2019-02-01 |
| US20190134057A1 (en) | 2019-05-09 |
| US12433898B2 (en) | 2025-10-07 |
| KR102482200B1 (ko) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3012791C (en) | Use of gabaa receptor modulators for treatment of itch | |
| Ralvenius et al. | Itch suppression in mice and dogs by modulation of spinal α2 and α3GABAA receptors | |
| Yu et al. | Complete restoration of hearing loss and cochlear synaptopathy via minimally invasive, single-dose, and controllable middle ear delivery of brain-derived neurotrophic Factor–Poly (dl-lactic acid-co-glycolic acid)-loaded hydrogel | |
| PT1478380E (pt) | Utilização de inibidores de tirosina-cinases para tratar doenças do snc | |
| WO2023089074A1 (en) | Autophagy inducing compounds and uses thereof, in particular for a systemic treatment of diseases and conditions | |
| Perez-Miller et al. | Peptide and peptidomimetic inhibitors targeting the interaction of collapsin response mediator protein 2 with the N-type calcium channel for pain relief | |
| Zuo et al. | ROS-responsive drug delivery system with enhanced anti-angiogenic and anti-inflammatory properties for neovascular age-related macular degeneration therapy | |
| EP3641763A2 (en) | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease | |
| RU2781636C2 (ru) | Применение модуляторов gabaa-рецептора для лечения зуда | |
| EP3856156B1 (en) | 5-ht7 antagonist for the treatment of dementia-associated tauopathies | |
| HK1262708A1 (en) | Use of gabaa receptor modulators for treatment of itch | |
| ITTO20110169A1 (it) | Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid | |
| EP3386510B1 (fr) | Derives phosphores pour la prevention ou le traitement des myopathies et traumatismes musculaires | |
| Schweizer | Evaluating the potential of TRESK-based gene therapy for the treatment of chronic pain | |
| Lin et al. | The Molecular Mechanisms and Therapeutic Potentials of Engrailed-1 in Fibrotic Scar Formation Post Glaucoma Filtration Surgery | |
| Chen et al. | Netrin-5 Preserves Blood-Brain Barrier Integrity via Wnt3a/β-Catenin Pathway Activation in Murine Cerebral Ischemia | |
| Albarran et al. | Postsynaptic synucleins mediate vesicular exocytosis of endocannabinoids | |
| Palanivel et al. | Selective Receptor Modulation by Truncated Neuropeptide Y (3–36) Dissociates Vasoconstriction from Neuroprotection in Experimental Glaucoma | |
| Yang et al. | Alamandine Attenuates Hypoxia-Induced Atrial Fibrosis and Atrial Fibrillation by Involving the YAP/TAZ Pathway | |
| WO2023126076A1 (en) | Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome | |
| Fontelonga | Development of Small Molecule Therapies Targeting Regeneration for the Treatment of Duchenne Muscular Dystrophy | |
| Boehme | Recombinant Expression of Sry3 Raises Blood Pressure Indices in Rattus norvegicus | |
| Amin | Epithelial Sodium Channels in the Brain: Effect of High Salt Diet on Their Expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240311 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241223 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241223 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250522 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250922 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251007 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251031 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251031 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251218 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251218 |